Trials / Recruiting
RecruitingNCT07039578
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM336 Injection(Low dose group) | subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol. |
| BIOLOGICAL | CM336 Injection(High dose group) | subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol. |
Timeline
- Start date
- 2025-07-25
- Primary completion
- 2026-06-30
- Completion
- 2029-07-31
- First posted
- 2025-06-26
- Last updated
- 2025-11-26
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07039578. Inclusion in this directory is not an endorsement.